Novartis, MSN Settle Patent Suit on Kisqali Cancer Treatments

Novartis AG and MSN Laboratories Pvt. Ltd. settled a dispute over patents for Novartis’ blockbuster Kisqali and Kisqali Femara Co-Pack, both used to treat advanced or metastatic breast cancer, according to a federal court filing.

Novartis and Otsuka Holdings Co.’s Astex Therapeutics unit, which share ownership of the three patents whose validity was the case’s only remaining issue, filed the stipulation and proposed order of dismissal along with MSN on Thursday in the US District Court for the District of Delaware. Neither Novartis nor MSN immediately responded to requests for comments.

The dismissal bars the parties from renewing all claims, ...